SCPH240816P5000
- 0.70
- 0.000.00%
scPharmaceuticals Newsroom
Analysts Have Conflicting Sentiments on These Healthcare Companies: ScPharmaceuticals (SCPH), Andlauer Healthcare Group (OtherANDHF) and Roche Holding AG (OtherRHHVF)
Furoscix Growth Prospects Anchor Buy Rating for ScPharmaceuticals
Analysts Are Bullish on These Healthcare Stocks: ScPharmaceuticals (SCPH), Optinose (OPTN)
ScPharmaceuticals Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Alcon (ALC), ScPharmaceuticals (SCPH) and Ascendis Pharma (ASND)
Buy Rating Affirmed for ScPharmaceuticals Amid Furoscix Success and Market Expansion
Craig-Hallum Remains a Buy on ScPharmaceuticals (SCPH)
Buy Rating Affirmed for ScPharmaceuticals Amidst Revenue Surge and Solid Financial Footing
ScPharmaceuticals Analyst Ratings
Analysts Have Conflicting Sentiments on These Healthcare Companies: Neurocrine (NBIX), Jazz Pharmaceuticals (JAZZ) and ScPharmaceuticals (SCPH)
Craig-Hallum Reaffirms Their Buy Rating on ScPharmaceuticals (SCPH)
Analysts Offer Insights on Healthcare Companies: ScPharmaceuticals (SCPH), Alnylam Pharma (ALNY) and AxoGen (AXGN)
Craig-Hallum Remains a Buy on ScPharmaceuticals (SCPH)
Buy Rating for ScPharmaceuticals: Furoscix's Market Traction and Growth Potential Drive Positive Valuation
Analysts Offer Insights on Healthcare Companies: Fate Therapeutics (FATE), ScPharmaceuticals (SCPH) and Invitae (NVTA)
ScPharmaceuticals' Growth Indicators and Future Potential: An Analysis of the Buy Rating and Furoscix's Rising Demand
Strong Market Performance and Growth Potential of Furoscics Propels ScPharmaceuticals to a 'Buy' Rating
Analysts Offer Insights on Healthcare Companies: Henry Schein (HSIC) and ScPharmaceuticals (SCPH)
Craig-Hallum Initiates Coverage On ScPharmaceuticals With Buy Rating, Announces Price Target of $20
ScPharmaceuticals Analyst Ratings